InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,187.60
(
-0.14%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
85.14
(
0.79%
)
Bitcoin
60,943.21
(
0.21%
)
Post# of 252390
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 05/26/2005 6:43:04 PM

Thursday, May 26, 2005 6:43:04 PM

Post# of 252390
Migraine Study Data from NMT Medical's MIST Study Presented at European Cardiology Conference

http://biz.yahoo.com/prnews/050524/netu015.html?.v=24

>>
High Incidence of PFO Heart Defect Reported in Migraine Patients

PARIS, May 24 /PRNewswire-FirstCall/ -- NMT Medical, Inc. (Nasdaq: NMTI - News), a leader in designing, developing and marketing minimally invasive solutions for the treatment of cardiac sources of migraine headaches, stroke and other potential brain attacks, today announced that data from its MIST (Migraine Intervention with STARFlex® Technology) study was reported at the EuroPCR meeting in Paris, the largest interventional cardiology meeting in Europe.

Data on the incidence of PFO observed in the MIST study was presented by Peter Wilmshurst, MD, at the Late-Breaking Trials session. In today's presentation, Dr. Wilmshurst said, "In our evaluation of 370 migraine patients, we found that 50% of them had a PFO (patent foramen ovale), which allows a right to left shunt, or flow, of venous blood into the arterial circulation. This important finding is consistent with earlier observational data and is twice what one would expect to find in the general population. In addition to PFOs, we found other shunts, predominately pulmonary, in another 10% of the migraine patients studied, which again is greater than what one would expect. What is remarkable is that more than 40% of the migraine patients studied had a large shunt; this is six times greater than what would be expected in the general population. By far, the PFO was the most prevalent large shunt we saw in the migraine patients, accounting for over 85% of all large shunts detected."

Dr. Wilmshurst, Consultant Cardiologist at Royal Shrewsbury Hospital, Shrewsbury, England, is co-primary investigator on the MIST study with Andrew J. Dowson, MD, Director of the King's Headache Service, Kings College Hospital, London.

Commenting on the MIST data, Dr. Dowson said, "The initial data from MIST is intriguing. We are not certain what causes migraine headaches. If, however, shunts like the PFO allow venous blood to enter the cerebral circulation, unfiltered and unmanaged by the lungs, perhaps that venous blood contains materials that trigger migraines in some patients. The next question the MIST study is designed to answer is whether closing the PFO with NMT's STARFlex® implant technology reduces or eliminates migraine headaches. We should be able to provide an answer to that question by the end of this year or early next year."

John E. Ahern, President and Chief Executive Officer of NMT Medical, said, "The preliminary data from MIST is very encouraging. It validates an important part of the equation for us in that half the migraine patients prospectively studied had a PFO. The data also gives us confidence in the potential size of the opportunity and our ongoing investment in clinical trials and new PFO closure technologies."

MIST is the first prospective, randomized, controlled study to evaluate the potential relationship between PFO and certain migraine headaches. The MIST study is designed to evaluate the effectiveness of NMT's STARFlex® implant technology in the treatment of these headaches. MIST is a double- blinded study randomizing migraine patients with a PFO to either PFO closure with STARFlex® or a control arm. MIST was approved in the United Kingdom in November 2004 and enrollment was initiated in January 2005. As previously announced, patient enrollment in MIST is expected to be completed by the end of June -- well ahead of its original schedule. Patients will be followed for six months. NMT expects the full results of MIST to be available in late 2005/early 2006.

About NMT Medical, Inc.

NMT Medical is an advanced medical technology company that designs, develops and markets proprietary implant technologies that allow interventional cardiologists to treat cardiac sources of migraine headaches, stroke and other potential brain attacks through minimally invasive, catheter- based procedures. NMT Medical is investigating the potential connection between a common cardiac defect called a PFO and brain attacks such as migraine headaches, stroke and transient ischemic attacks (TIAs). A PFO can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 16,000 PFOs have been closed globally with NMT's minimally invasive, catheter-based implant technology.

The prevalence of migraines in the United States is about 10%. Of the 28 million migraine sufferers in America, those who experience aura and have a PFO may represent a three million patient subset. Stroke is the third leading cause of death in the United States and the leading cause of disability in adults. Each year, 750,000 Americans suffer a new or recurrent stroke and 500,000 Americans experience a TIA.

The Company also serves the pediatric interventional cardiologist with a broad range of cardiac septal repair implants delivered with nonsurgical catheter techniques. For more information about NMT Medical, please visit http://www.nmtmedical.com.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up